OncoMed Pharmaceuticals, Inc. (OMED) Rises A lot Today, Is Now One of The Best Performer

December 7, 2017 - By Linda Rogers

Investors sentiment decreased to 0.59 in 2017 Q2. Its down 0.65, from 1.24 in 2017Q1. It dived, as 26 investors sold OncoMed Pharmaceuticals, Inc. shares while 23 reduced holdings. 12 funds opened positions while 17 raised stakes. 17.17 million shares or 17.60% more from 14.60 million shares in 2017Q1 were reported.
Meeder Asset Mgmt, Ohio-based fund reported 799 shares. Blackrock reported 781,773 shares. Tower Rech Capital Limited Liability Company (Trc) stated it has 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Citigroup Incorporated accumulated 1,670 shares or 0% of the stock. Birchview Cap L P reported 28,689 shares or 0.05% of all its holdings. Credit Suisse Ag accumulated 0% or 44,484 shares. Tudor Corporation Et Al holds 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) or 22,900 shares. Morgan Stanley reported 28,579 shares stake. Glenmede Trust Na reported 12,900 shares. Goldman Sachs Gp has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 170,439 shares. The California-based Wells Fargo Communication Mn has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Vanguard Group Incorporated reported 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). 407,741 are held by Cannell Peter B & Inc. Susquehanna Grp Llp has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). The British Columbia – Canada-based Connor Clark Lunn Mgmt Limited has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED).

The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is a huge mover today! The stock increased 8.23% or $0.38 during the last trading session, reaching $5. About 226,559 shares traded or 49.12% up from the average. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 70.06% since December 7, 2016 and is downtrending. It has underperformed by 86.76% the S&P500.
The move comes after 5 months positive chart setup for the $189.28 million company. It was reported on Dec, 7 by Barchart.com. We have $5.35 PT which if reached, will make NASDAQ:OMED worth $13.25M more.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on March, 14. They expect $-0.32 earnings per share, up 54.29 % or $0.38 from last year’s $-0.7 per share. After $-0.28 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29 % negative EPS growth.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Ratings Coverage

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, September 22 by H.C. Wainwright. The rating was maintained by Jefferies with “Buy” on Tuesday, September 26. BMO Capital Markets initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, April 12 with “Outperform” rating. On Monday, January 25 the stock rating was downgraded by Leerink Swann to “Mkt Perform”. On Monday, April 18 the stock rating was initiated by Cantor Fitzgerald with “Buy”. SunTrust initiated it with “Buy” rating and $16 target in Tuesday, December 20 report. As per Tuesday, April 11, the company rating was downgraded by BMO Capital Markets. Mizuho maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Wednesday, January 6. Mizuho has “Neutral” rating and $40 target. The rating was maintained by Jefferies on Wednesday, August 10 with “Buy”. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Outperform” rating given on Friday, December 4 by Wells Fargo.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Marketwatch.com which released: “OncoMed Pharma stock drops 45% after midstage clinical trial miss; Bayer …” on April 10, 2017, also Globenewswire.com with their article: “OncoMed Announces Workforce Reduction” published on April 24, 2017, Seekingalpha.com published: “OncoMed Pharmaceuticals’ (OMED) CEO Sunil Patel on Q3 2017 Results – Earnings …” on November 05, 2017. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: Seekingalpha.com and their article: “OncoMed Pharmaceuticals: Is This $4.50 Busted IPO A Buy?” published on September 29, 2017 as well as Globenewswire.com‘s news article titled: “OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence” with publication date: September 19, 2017.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $189.28 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.